Interaction potential of the dual orexin receptor antagonist ACT-541468 with CYP3A4 and food: results from two interaction studies
Sign Up to like & getrecommendations! Published in 2018 at "European Journal of Clinical Pharmacology"
DOI: 10.1007/s00228-018-2559-5
Abstract: PurposeACT-541468 is a novel dual orexin receptor antagonist (DORA) under development for the treatment of insomnia. In vitro studies suggested a significant role of CYP3A4 in ACT-541468 metabolism and an impact on CYP3A4 activity.MethodsSubsequently, two… read more here.
Keywords: act; act 541468; dual orexin; interaction ... See more keywords
Multiple-dose clinical pharmacology of ACT-541468, a novel dual orexin receptor antagonist, following repeated-dose morning and evening administration
Sign Up to like & getrecommendations! Published in 2019 at "European Neuropsychopharmacology"
DOI: 10.1016/j.euroneuro.2019.05.009
Abstract: ACT-541468 is a dual orexin receptor antagonist with sleep-promoting effects in humans. Following entry-into-humans, its pharmacokinetics (PK) including dose-proportionality and accumulation, pharmacodynamics (PD), safety, and tolerability following multiple-ascending oral dose (MAD) administration in the morning,… read more here.
Keywords: evening administration; pharmacology; act 541468; multiple dose ... See more keywords